Uterine Microbiome and IVF Implantation: What We Know
Can the bacteria in your uterus affect whether an embryo implants?
Possibly, and the evidence is stronger than it was five years ago — but it is still association, not proof. Studies consistently find that women whose uterine lining is dominated by Lactobacillus species tend to have better implantation and pregnancy outcomes than women whose lining carries a more mixed bacterial community. What nobody has shown yet is that changing those bacteria on purpose reliably changes whether a transfer works, which is why microbiome testing is not part of standard care and probiotics are not a treatment.
Wasn't the uterus supposed to be sterile?
That was the teaching for most of the last century, and it was wrong. Sequencing the bacterial 16S rRNA gene showed that the endometrium carries its own low-biomass microbial community, distinct in some women from the vagina below it.
"Low biomass" is the important phrase. There is far less bacterial material in the uterus than in the vagina or gut, which makes the sampling itself a scientific problem. A catheter passing through the cervix can carry vaginal bacteria with it, and reviews of this literature openly state that vaginal contamination during sampling cannot be ruled out — one of the reasons researchers still have no agreed definition of a "healthy" uterine microbiome.
So when you read that a test can tell you whether your uterus has the right bacteria, understand what is underneath that claim: a young field, no sampling consensus, and a moving target.
What did the 2026 Lactobacillus gasseri study actually find?
This is the study getting the attention, and it is a genuinely interesting one. Published in Cell Host & Microbe in August 2026, it analyzed endometrial samples from 149 women aged 20 to 45 who were being treated for infertility, grouped as under 30, 30 to 35, and over 35.
Two findings matter. First, the youngest group had significantly more Lactobacillus in the lining, and L. gasseri specifically declined with age. Second, of the women who went on to embryo transfer, those who became pregnant had a higher endometrial abundance of Lactobacillus than those who did not.
The researchers then went further than most microbiome papers do. In human endometrial cells and in older mice, they tested a sugar molecule produced by L. gasseri — an exopolysaccharide, studied as a postbiotic rather than a live probiotic. In those experimental models it reduced markers of inflammation, oxidative stress and cellular aging in the lining, and treated older mice had higher embryo implantation rates.
That is a plausible biological pathway, tested in cells and animals. It is not a human treatment. The study's own senior author cautioned women against self-medicating with over-the-counter L. gasseri products, and said the work cannot prove that microbiome changes cause endometrial aging or poor outcomes. Nobody has given this postbiotic to a woman before a transfer in a trial.
Is chronic endometritis the same thing as a bad microbiome?
No, and this distinction is where the conversation usually gets muddled. Chronic endometritis is an actual diagnosis — persistent, low-grade inflammation of the lining, identified by staining a biopsy for plasma cells using the CD138 marker. It is a pathology report, not a bacterial abundance score.
It is also the part of this story with the most clinical traction. A 2024 systematic review and meta-analysis found chronic endometritis in about one in five infertile women compared with roughly one in thirteen controls, and found a strong association with recurrent pregnancy loss — present in over a third of loss cases versus about a sixth of controls. Notably, that same analysis did not find a significant association with recurrent implantation failure, even though individual studies have reported it in a third of women with repeated failed transfers. The literature disagrees with itself here, and honest reading means saying so.
Treatment evidence is similarly split. Reviews of antibiotic treatment for chronic endometritis report conflicting results, and the European guidance on recurrent implantation failure lands on "antibiotics can be considered" rather than a recommendation. That is a decision for the physician managing your cycle, made from your biopsy — not something to infer from a swab.
Do cervical and vaginal swabs predict IVF outcomes?
Some research says they carry signal. A prospective Dutch study published in Human Reproduction profiled the vaginal microbiome before IVF or ICSI and was able to stratify women by their chance of becoming pregnant before treatment started, with certain profiles — including some dominated by Lactobacillus crispatus — associating with better odds and dysbiotic profiles with worse ones.
Stratifying risk is not the same as improving it. A profile that predicts a lower chance does not come with an intervention that raises it, and in a low-biomass environment the swab is measuring the vagina and cervix, not the cavity where the embryo lands. Useful research direction; not yet a decision tool.
Should you take a probiotic before an embryo transfer?
That is a question for the physician running your transfer cycle, and here is the honest state of the evidence to bring to that conversation.
Randomized trials of vaginal Lactobacillus before frozen transfer exist, and they are mixed. The largest, in Scientific Reports in 2023, randomized 340 women and found no difference in biochemical or clinical pregnancy rates overall; it did report a significantly lower miscarriage rate and a higher live birth rate in the blastocyst subgroup, both of which are secondary findings from subgroups rather than the outcome the trial was built to answer. A smaller 2026 trial of a vaginal synbiotic reported higher chemical and clinical pregnancy rates, with ongoing pregnancy and implantation not reaching significance.
Meanwhile, oral capsules, vaginal products and laboratory postbiotics are not interchangeable — different strains, different doses, different destinations in the body. And "natural" does not mean neutral during a medicated cycle. Anything you take before a transfer belongs on the list you give your reproductive endocrinologist, which is also true of supplements you started long before this cycle.
What do we look at instead when a transfer keeps failing?
Here in Huntington, the microbiome comes up in evaluations often, and we treat it the way the evidence supports: as one input into the uterine environment, not the explanation for a failed cycle. The lining is downstream of things we can actually measure and move.
That means looking at the inflammatory and metabolic picture around implantation — blood sugar and insulin, thyroid function, inflammatory and immune markers, clotting factors, and blood flow to the uterus. When women come to us across Long Island after a euploid embryo has failed to stick, those systems are where we find something to change more often than not. If you want a structured read on which of those pathways is most likely to be at play in your case, our fertility assessment is the fastest way to see it laid out, and we go through the same territory in more depth in why implantation keeps failing and in our IVF and IUI support work alongside your clinic.
There is also a real connection between this research and the estrogen-clearance work we have written about — both are examples of bacteria influencing a hormonal or inflammatory environment that a standard workup never examines. If that interests you, gut bacteria and estrogen clearance covers the other half of it, and inflammation and fertility covers the mechanism they share.
The honest summary
The uterine microbiome is real, it correlates with implantation, and the 2026 postbiotic work gives researchers a mechanism worth chasing. None of that makes it testable-and-treatable today. Microbiome profiling is not recommended as routine care, several endometrial add-ons marketed for repeated implantation failure are listed as not recommended by the American Society for Reproductive Medicine on the grounds that they have not been shown to improve live birth, and the postbiotic that made headlines has never been trialed in a person.
What that leaves is the unglamorous work: treat diagnosed chronic endometritis with your physician, take the inflammatory and metabolic terrain seriously, and be skeptical of any test sold as the answer to a question this field has not settled. That is the conversation we would rather have with you before your next transfer than after it.
This article is for general educational purposes and isn't a substitute for individualized guidance from your OB-GYN or reproductive endocrinologist. Decisions about microbiome or endometrial testing, antibiotics, probiotics, or anything else taken during a transfer cycle should be made with the physician managing that cycle.
East to West Fertility is a metabolic and immune-focused fertility clinic in Huntington, Long Island, serving patients across Long Island, NYC, and beyond. Learn more about our Metabolic & Immune Fertility Evaluation or call 631-416-4940.
References:
- Li et al. "Lactobacillus gasseri postbiotics ameliorate age-related decline in endometrial receptivity." Cell Host & Microbe, 2026 (149 endometrial samples; cell and mouse models).
- Moreno I, Simón C, et al. "Evidence that the endometrial microbiota has an effect on implantation success or failure." American Journal of Obstetrics & Gynecology, 2016 (PubMed 27717732) — Lactobacillus-dominated vs non-dominated definition.
- "Chronic endometritis and recurrent reproductive failure: a systematic review and meta-analysis." Frontiers in Immunology, 2024. doi:10.3389/fimmu.2024.1427454.
- Kitaya K, et al. "Live birth rate following oral antibiotic treatment for chronic endometritis in infertile women with repeated implantation failure." American Journal of Reproductive Immunology, 2017. doi:10.1111/aji.12719.
- ESHRE Working Group. "ESHRE good practice recommendations on recurrent implantation failure." Human Reproduction Open, 2023 (PMC10270320) — microbiome profiling and antibiotics for chronic endometritis.
- Koedooder R, et al. "The vaginal microbiome as a predictor for outcome of in vitro fertilization." Human Reproduction, 2019. doi:10.1093/humrep/dez065.
- Thanaboonyawat I, et al. "Pregnancy outcomes after vaginal probiotic supplementation before frozen embryo transfer: a randomized controlled study." Scientific Reports, 2023;13. doi:10.1038/s41598-023-39078-6.
- "The Endometrial Microbiota: Challenges and Prospects." Medicina, 2023. doi:10.3390/medicina59091540 — low biomass and sampling contamination.
- Practice Committee of the American Society for Reproductive Medicine. "Recurrent implantation failure: a committee opinion," 2026.
